This finding indicates that after developing resistance from first-line mefatinib, osimertinib, and other therapeutic strategies or guidelines currently in use for managing NSCLC after progression from prior generations of EGFR-TKI remains applicable after mefatinib progression. This evidence concerns the gene EGFR and non-small cell lung carcinoma.